Barclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Barclays PLC bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 54,886 shares of the company’s stock, valued at approximately $731,000.

A number of other institutional investors and hedge funds have also modified their holdings of ETON. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $90,000. Raymond James Financial Inc. acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $147,000. Hillsdale Investment Management Inc. purchased a new position in Eton Pharmaceuticals during the fourth quarter valued at approximately $226,000. Envestnet Asset Management Inc. acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at approximately $236,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Eton Pharmaceuticals in the 4th quarter worth approximately $373,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ETON shares. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. B. Riley reaffirmed a “buy” rating and set a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Finally, Craig Hallum boosted their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Trading Down 2.2 %

Shares of NASDAQ:ETON opened at $16.60 on Wednesday. The stock has a market capitalization of $445.07 million, a PE ratio of -75.44 and a beta of 1.22. Eton Pharmaceuticals, Inc. has a 1 year low of $3.18 and a 1 year high of $18.41. The firm has a fifty day moving average price of $14.34 and a 200 day moving average price of $13.41.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. On average, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.